Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immuneering (IMRX) Total Current Liabilities (2020 - 2026)

Immuneering's Total Current Liabilities history spans 7 years, with the latest figure at $5.0 million for Q1 2026.

  • On a quarterly basis, Total Current Liabilities fell 2.62% to $5.0 million in Q1 2026 year-over-year; TTM through Mar 2026 was $5.0 million, a 2.62% decrease, with the full-year FY2025 number at $10.1 million, up 34.25% from a year prior.
  • Total Current Liabilities came in at $5.0 million for Q1 2026, down from $10.1 million in the prior quarter.
  • The five-year high for Total Current Liabilities was $10.1 million in Q4 2025, with the low at $3.7 million in Q1 2022.
  • Historically, Total Current Liabilities has averaged $6.5 million across 5 years, with a median of $6.8 million in 2024.
  • Peak annual rise in Total Current Liabilities hit 50.41% in 2023, while the deepest fall reached 22.51% in 2023.
  • Year by year, Total Current Liabilities stood at $8.1 million in 2022, then decreased by 2.59% to $7.8 million in 2023, then decreased by 4.36% to $7.5 million in 2024, then surged by 34.25% to $10.1 million in 2025, then crashed by 50.62% to $5.0 million in 2026.
  • Business Quant data shows Total Current Liabilities for IMRX at $5.0 million in Q1 2026, $10.1 million in Q4 2025, and $9.5 million in Q3 2025.